Previous close | 21.76 |
Open | 21.97 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 21.87 - 21.97 |
52-week range | 11.85 - 23.20 |
Volume | |
Avg. volume | 2,682 |
Market cap | N/A |
Beta (5Y monthly) | 0.78 |
PE ratio (TTM) | 0.06 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Royal Philips (PHG) is recalling about 150 MRI machines in the US on concerns of explosion risks caused by a buildup of helium gas. The medical device company says it has inspected about 95% of the recalled machines in the US and plans to complete the rest of the inspections shortly. Shares of Royal Philips fell about 1%. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Royal Philips's (PHG) strategic transformation from consumer electronics to healthcare innovation is well underway. The company's goal is to improve the lives of three billion people a year by 2025. But the transition has been a bumpy ride for investors. Shares of the Dutch manufacturer have slumped amid a recall of its sleep apnea devices. Royal Philips CEO Roy Jakobs joins Yahoo Finance Live to discuss the recalls as well as the company's measured adoption of AI-powered solutions. "We do it in a responsible manner... The National Academy of Medicine has gathered tech companies, providers, regulators and government officials to develop a code of conduct for responsible AI application," Jakobs said. "AI can come to the rescue but, of course, you need to be aware of what it can and cannot do." Jakobs added: "The closer you get to the patient, the more careful you need to be." Click here to watch the full interview on the Yahoo Finance YouTube page or you can watch this full episode of Yahoo Finance Live here.
Shares of Royal Philips (PHG) tumbled in early trading on Friday after the U.S. Food and Drug Administration said it was not satisfied with how the company handled a recall of its breathing device that is used to help treat sleep apnea. In a statement, the Director of the FDA's Center for Devices and Radiological Health Dr. Jeff Shuren says "we do not believe that the testing and analysis Philips has shared to date are adequate to fully evaluate the risks posed to users from the recalled devices." Yahoo Finance Live breaks down the stock's reaction. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.